CFA
BIO icon

Cahill Financial Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Cahill Financial Advisors’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-20
Closed -$15K – 285
2021
Q3 		$15K Buy
+20
New +$15K ﹤0.01% 489

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Cahill Financial Advisors's BIO Position: Q4 2021 in Review

Cahill Financial Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2021, closing a stake of 20 shares — an estimated $15K sold.

Cahill Financial Advisors first reported a position in BIO in Q3 2021 and held it in 1 quarter. The position peaked at $15K in Q3 2021. 533 funds tracked by Wall St. Rank hold BIO as of Q4 2021.

  • Cahill Financial Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q4 2021 after selling out during the quarter.
  • Cahill Financial Advisors sold 20 Bio-Rad Laboratories Class A shares in Q4 2021, an estimated $15K.
  • Cahill Financial Advisors first reported a position in Bio-Rad Laboratories Class A in Q3 2021 and held it in 1 quarter.
  • Cahill Financial Advisors's Bio-Rad Laboratories Class A position peaked at $15K in Q3 2021.
  • 533 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2021.

Based on Cahill Financial Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.